Repros Therapeutics (RPRX) Submits Data to the FDA Supporting Morning Assessment of Testosterone for Men Treated with Androxal(R)

Dec. 23, 2010 (Business Wire) — Repros Therapeutics Inc.^® (NasdaqCM:RPRX) today announced it has submitted to the FDA data collected from three different studies which the Company believes demonstrates that the assessment of testosterone levels between 8 and 10 in the morning is indicative of the maximum and average levels of the male hormone achieved during a particular day following the administration of Androxal^®. In the Type B meeting held on November 8, 2010, and reported in the Company’s press release of November 9, 2010, the FDA stated the preferred method to determine testosterone levels in treatments designed to replace the hormone is a 24 hour assessment.

Repros used the services of an outside statistician, Dr. Richard Trout, Professor Emeritus, Rutgers University, in arriving at the conclusions it has reached.

The Company has conducted three trials in which serial testosterone measurements were made over a 24 hour period. Two of the studies assessed 14 (ZA-002) and 11 (ZA-003 subset) time points over the 24 hour period in a total of 28 subjects. A third study (ZN-018) obtained measurements at six points in a total of 20 subjects.

Using the data from the 002 and 003 studies the sponsor has determined that a single total testosterone assessment made between 8 and 10 in the morning correlates to the average of the values of the testosterone measurements for a given subject on a given day (correlation coefficient roughly 0.9 for the times 8, 9 and 10, p value < 0.001).

Performing the same assessment for the maximum value of total testosterone recorded in a 24 hour period, the same single total testosterone assessment made between 8 and 10 in the morning correlates to the maximum value of testosterone for a given subject on a given day (correlation coefficient roughly 0.9 for the times 8, 9 and 10, p value < 0.001).

From the 018 study that assessed men at baseline and after 14 days of treatment, the Company observed that Androxal raises each time point testosterone level by an average of 200 ng/dl at 12.5 mg and 260 ng/dl at a 25 mg dose.

Unlike topical testosterone preparations, Androxal maintains the normal daily rhythm of testicular testosterone production with peak levels generally occurring in the morning and trough levels exhibited in the evening. The testosterone levels achieved by the administration of topical preparations are a function of a variety of factors none of which relate to the normal daily rhythm. In some instances, subject to subject variability can lead to supernormal levels of testosterone several hours after administration of the topical preparations. The Company has committed to conduct one additional 24 hour study to show that Androxal’s action in maintaining the normal rhythm is both predictable and dose dependent.

About Repros Therapeutics Inc.

Repros Therapeutics focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros’ ability to have success in its ongoing clinical trials, raise needed additional capital on a timely basis in order for it to continue to fund its operations and pursue its development activities, and such other risks which are identified in the Company’s most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company’s website at http://www.reprosrx.com.

Repros Therapeutics Inc.

Joseph Podolski, (281) 719-3447

President and Chief Executive Officer

Subaye, Inc. (SBAY) Announces Fiscal Year 2010 Adjusted EBITDA Increased 53.9%

Ivanhoe Energy (IE.TO) Announces Significant Natural Gas Discovery at Yixin-2 Well

CALGARY, Dec. 21 /PRNewswire/ – David Dyck, President and Chief Operating Officer of Ivanhoe Energy Inc. (TSX:IE.to – News), Robert Friedland, Co-Chairman of Ivanhoe Energy’s China-focused subsidiary, Sunwing Energy Ltd., and Gerry Moench, President of Sunwing, today announced a significant gas discovery at Sunwing’s Yixin-2 well in Southwest China.

Gas from the well flowed at rates of up to 13 million cubic feet per day, and averaged 9 to 10 million cubic feet per day during the initial 24-hour test period. Gas is flowing from the Xu-4 Formation, a well established gas-producing formation in the region.

“We’re very pleased with these initial flow rates,” Mr. Dyck said. “The rates recorded from the Xu-4 Formation demonstrate the discovery’s strong potential and are incentive for Sunwing to continue with further development of the Xu-4 formation, and other structures in the Zitong Block.”

Following initial flow and pressure tests, the well has now been shut-in for pressure build-up.

Sunwing’s 659,840-acre (1,031-square-mile) Zitong Block is in the Sichuan Province; the oldest and one of the most productive gas-producing regions in China. Sinopec and PetroChina have made significant gas discoveries from the Xu-2, Xu-4 and Permian formations in adjacent blocks.

“It has taken over ten years of perseverance and the application of industry-leading experience and know-how to reach this point,” said Mr. Friedland. “Demand for natural gas in China is continuing to out-pace supply and now Sunwing Energy is in an excellent position to help supply this burgeoning market on very favourable commercial terms through an established collection and distribution system.”

Technical teams from Sunwing and PetroChina are working to develop a strategy to evaluate the Yixin structure, as well as the potential for further discoveries elsewhere on the Zitong Block.

Sunwing is the operator of the Zitong exploration block in Sichuan and holds a 90% Contractor Interest in a Petroleum Contract with PetroChina Company Limited. Mitsubishi Gas Chemical Company of Japan holds the remaining 10% Contractor Interest.

Ivanhoe Energy Inc. is an independent, international heavy oil development and production company focused on pursuing long-term growth in its reserves and production using advanced technologies, including its proprietary, patented heavy to light upgrading process (HTL™). Core operations are in Canada, Ecuador, China and Mongolia, with business development opportunities worldwide. Ivanhoe’s shares trade on the NASDAQ Capital Market with the ticker symbol IVAN and on the Toronto Stock Exchange under the symbol IE.

FORWARD-LOOKING STATEMENTS: This document includes forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the estimated quantities of gas in each target in the Guan structure, the planned total depth of the Zitong-1 well, the anticipated amount of time required for, and the estimated cost of, drilling, testing and casing the well, the schedule for commencement of drilling the Yinxin-2 well and other statements which are not historical facts. When used in this document, the words such as “could”, “plan”, “estimate”, “anticipate”, “intend”, “may”, “potential”, “should”, and similar expressions relating to matters that are not historical facts are forward-looking statements. Although Ivanhoe Energy and Sunwing Energy believe that their expectations reflected in these forward-looking statements are reasonable, such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Important factors that could cause actual results to differ from these forward-looking statements include the possibility that the company will be unable to raise financing, the potential that the company’s projects will experience technological and mechanical problems, geological conditions in reservoirs may not result in commercial levels of oil and gas production, the availability of drilling rigs and other support services, uncertainties about the estimates of the reserves, the risk associates with doing business in foreign countries, environmental risks, changes in product prices, our availability to generate cash flow and raise capital as and when required, competition and other risks disclosed in Ivanhoe Energy’s Annual Report on Form 10-K files with the U.S. Securities and Exchange Commission on EDGAR and the Canadian Securities Commissions on SEDAR.

For more information about Ivanhoe Energy Inc. please visit our web site at www.ivanhoeenergy.com.

WidePoint’s (WYY) ARCC Subsidiary Deploys Phase 2 of DOJ Crime Scene Management Technology Project in Delaware

WASHINGTON, Dec. 21, 2010 /PRNewswire/ — WidePoint Corporation (NYSE Amex: WYY), a specialist in wireless mobility management and cybersecurity solutions, today announced that its Advanced Response Concepts Corporation subsidiary released the Beta version of its crime scene management and evidence tracking system, deploys phase two of the U.S. Department of Justice technology grant with academic partner Delaware State University and its Department of Public Safety.

ARCC’s CONDOR system is a specialized solution that enables crime scene investigators to digitally document evidence found in the field, and to identify, label and track evidence throughout the chain of custody. This tablet-based system integrates embedded barcode or RFID-tagged evidence markers, provides for biometric attendance and tracking records at the crime scene, and is interoperable with the U.S. National Information Exchange Model (NIEM) compliance system.

Demonstrations of CONDOR can be viewed on ARCCTV YouTube Channel at http://www.youtube.com/watch?v=Z58V0iG83ng. In addition, WBOC, Channel 16, covered the testing of the system in a recent report, which can be viewed at http://bit.ly/dMCPA4.

Daniel E. Turissini, CEO of Advanced Response Concepts Corporation stated, “We have delivered a solution that combines a proven technology with the best investigative techniques, allowing every investigator and department to work effectively and with complete confidence in the evidence chain of custody. We believe our solution is a true force-multiplier, at a time when the courts and the public demand ever greater accountability in the collection and preservation of crime scene evidence.”

WidePoint’s CEO, Steve L. Komar, added, “This is yet another example of our efforts to expand the reach of our industry-leading product offerings beyond the Federal space. We are excited to complete this latest phase of the DOJ technology project for these crime scene investigation support systems targeted for law enforcement agencies nationwide. We look forward to demonstrating the robustness of this product and meeting the needs, within and outside of the State of Delaware, of the priorities in addressing the needs of Public Safety professionals across the nation.”

About WidePoint

WidePoint is a specialist in providing wireless mobility management and cybersecurity solutions utilizing its advanced information technology products and services. WidePoint has several wholly owned subsidiaries holding major government and commercial contracts including, Operational Research Consultants, Inc., iSYS, LLC, Protexx Technology Corporation, Advanced Response Concepts Corporation and WidePoint IL. WidePoint enables organizations to deploy fully compliant IT services in accordance with government-mandated regulations and advanced system requirements. For more information, visit http://www.widepoint.com

China Armco Metals (CNAM) Provides Update on Metal Recycling Business

SAN MATEO, CA–(Marketwire – 12/21/10) – China Armco Metals, Inc. (AMEX:CNAM – News) (“China Armco” or the “Company”), a distributor of imported metal ore and metal recycler with a new state-of-the-art scrap metal recycling facility in China, today announced it expects the Company to produce and sell approximately 25,500 tons of recycled steel with an aggregate value of approximately $12 million in the fourth quarter of 2010.

China Armco’s fourth quarter orders to sell 25,500 tons of recycled steel are from 5 customers. The central government recently announced that the power rationing for energy intensive industries and steel producers will be phased out and the Company is optimistic about being able to be operating on a full time basis in the near term.

“We are encouraged by recent actions by the central government to relax the power restrictions,” remarked Mr.Kexuan Yao, the Company’s Chairman and Chief Executive Officer. “Recycled steel produced through our state-of-the-art production facility, which uses less electricity and emits less air pollution than steel produced through traditional iron ore processing, is poised to benefit from the central government’s new policies. We are working diligently to secure additional scrap metal in order to service the pent up demand for recycled steel in China.”

About China Armco Metals, Inc.

China Armco Metals, Inc. is engaged in the sale and distribution of metal ore and non-ferrous metals throughout the PRC and has entered the recycling business with the recent launch of operations of a 80,000 ton per year shredder and recycler of metals located on 32 acres of land. China Armco maintains customers throughout China which includes the fastest growing steel producing mills and foundries in the PRC. Raw materials are acquired from a global group of suppliers located diverse countries, including, but not limited to, India, Hong Kong, Nigeria, Brazil, Turkey and the Philippines. China Armco’s product lines include ferrous and non-ferrous ore, iron ore, chrome ore, nickel ore, magnesium, copper ore, manganese ore and steel billet. The recycling facility is expected to be capable of recycling one million metric tons of scrap metal per year which will position China Armco as one of the 10 largest recyclers of scrap metal in China. China Armco estimates the recycled metal market in China as 70 million metric tons. For more information about China Armco, please visit http://www.armcometals.com.

Safe Harbor Statement

In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, China Armco Metals, Inc., is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects”) may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations regarding our revenues and production related to our scrap metal recycling operations and the extent of government imposed blackouts and the impact on our recycling operations. In addition, any such statements are qualified in their entirety by reference to, and are accompanied by, the following key factors that have a direct bearing on our results of operations:

We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by our partner’s ability to complete its obligations to source various minerals and ores within acceptable specifications, demand and fluctuations in the prices of those minerals and ores, our ability to resell any sourced minerals and ores at current market prices and on favorable terms, our ability to finance the purchase price of any minerals and ores, and the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended December 31, 2009.

For more information, please contact:
Investor Relations:
HC International, Inc.
Ted Haberfield, Executive VP
Tel: +1-760-755-2716
Email: thaberfield@hcinternational.net
Web: www.hcinternational.net
Company:
US Contact:
Oliver Hu
Investor Relations
China Armco Metals, Inc.
Office: 650.212.7620
Email: oliver@armcometals.com
Website: www.armcometals.com
China Contact:
Wayne Wu
China Armco Metals, Inc.
Office: 021-62375286
Email: wayne.wu@armcometals.com
Website: www.armcometals.com

Pernix Therapeutics (PTX) Establishes Joint Venture with SEEK

Dec. 20, 2010 (Business Wire) — Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX) (“Pernix”), an integrated specialty pharmaceutical company focused primarily on the pediatric market, today announced the establishment of a new joint venture with SEEK, a leading United Kingdom private drug-discovery group. The joint venture will undertake the late-stage development and registration of BC1036, a first-in-class antitussive drug designed to address the serious need for a safer and more effective, non-opioid treatment for persistent cough. Both parties also licensed or assigned all of their theobromine intellectual property to the joint venture.

Following consultation with a European regulatory authority, the new venture will conduct a single pivotal Phase III trial of BC1036, which is expected to begin in the first half of 2011. This truncated regulatory path is due to the significant historical safety data available for theobromine and the beneficial effect seen in human use to date. The new venture is also in discussions with the United States Food and Drug Administration and expects to confirm early next year the regulatory program.

Theobromine is a well known, safe product that is found in existing medicines and significant quantities of cocoa-based products including chocolate and as a metabolite of caffeine. Based on a review of available data, Pernix believes theobromine has been shown to inhibit the inappropriate firing of the vagus nerve which is a key feature of persistent cough. This peripheral mechanism of action differentiates theobromine from codeine and other centrally acting agents, which Pernix believes leads to its lower central nervous system side effect.

Persistent cough is a very common condition, affecting an estimated 10-12.5%¹ of people globally. In persistent cough, symptoms persist for more than two weeks and may arise mainly from cough predominant asthma, oesophageal reflux and rhinitis. The cough market has seen little to no innovation over the past twenty years despite the side-effects associated with current treatments. The Commission on Human Medicines and its Paediatric Medicines Expert Advisory Group advised that codeine, a drug used in most common cough treatments, should be withdrawn from use by children under the age of 18 in the OTC market in the United Kingdom.

Based on the successful launch of BC1036 in 2009 as AnyCough™ in Korea and the resulting substantial data package, BC1036 has the potential to be on the market in Europe and the U.S. within two years from trial commencement, subject to receiving marketing authorization. The new venture is collaborating closely with leading experts in the U.K. — Professor Morice, Head of Hull Cough Clinic, and Professor Ian Pavord, University Hospitals Leicester.

Professor Alyn Morice, Head of the Hull Cough Clinic, commented: “Thousands of people across the U.K. suffer from persistent cough and, due to the drawbacks of current opioid drugs such as codeine, we are in desperate need of a non-opioid treatment with a drastically improved side effect profile for patients.”

Professor Ian Pavord, Department of Respiratory Medicine and Thoracic Surgery, Glenfield Hospital, Leicester, commented: “Persistent cough is a highly debilitating condition that severely impacts the lives of sufferers and their family and friends. Currently available treatment options are limited and often associated with negative side effects. The existing human data on BC1036 is very exciting and I look forward to being in a position to offer an effective and safe drug to our patients.”

Manfred Scheske, who has recently joined SEEK as CEO of Consumer Health, will provide leadership to the development of BC1036. Mr. Scheske was formerly President of Consumer Healthcare Europe at GlaxoSmithKline (“GSK”), where he enjoyed a highly successful 25-year career with GSK in Europe, North America and at a global level within GSK’s Consumer Healthcare Leadership Team.

Commenting on this announcement, Manfred Scheske, CEO of Consumer Health at SEEK, said: “I am very excited that we have funding for the late-stage development of BC1036, which has the potential to dramatically impact the treatment of persistent cough and could greatly benefit the quality of life of persistent cough sufferers. Utilizing my extensive U.S. and European experience from GSK, I am very much looking forward to taking this program forward towards commercialization and to announcing the commencement of our Phase III trial next year.”

Cooper Collins, President and CEO of Pernix, said: “This partnership is an exciting step forward in the growth of our company and provides an opportunity to increase our share of the approximately $3 billion global market for prescription and OTC cough suppressants. By partnering with SEEK, we are able to advance this novel codeine-free natural cough suppressant in a more cost-effective and lower risk regulatory path. Given the lack of new treatments for persistent cough over the last two decades, we believe that our non-opiate antitussive medicine offers an innovative alternative treatment for persistent cough sufferers and look forward to working with SEEK to advance the development of BC1036 through commercialization in Europe and the U.S.”

About Pernix Therapeutics

Pernix Therapeutics Holdings, Inc. is an integrated specialty pharmaceutical company primarily focused on serving the needs of the pediatric marketplace. Commercially-proven branded product families include CEDAX®, Brovex®, Aldex®, Pediatex®, ReZyst®, QuinZyme® and Z-Cof®. The Company was originally founded in 1999 and is based in the Houston, TX metropolitan area. Additional information about Pernix is available on the Company’s website located at www.pernixtx.com.

Cautionary Notice Regarding Forward-Looking Statements

The Company wishes to caution readers not to place undue reliance on any forward-looking statements, which speak only as of the date made. No assurances can be given regarding the future performance of the Company. The Company wishes to advise readers that factors could affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements.

The Company does not undertake, and specifically declines any obligation, to publicly release the result of any revisions which may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

1. Department of Cardiovascular and Respiratory Studies, University of Hull, Castle Hill Hospital, Cottingham, East Yorkshire, UK, a.h.morice@hull.ac.uk

Pernix Therapeutics Holdings, Inc.

Tracy Clifford, 843-720-1501

Chief Financial Officer

or

The IGB Group

Investor Relations and Media Contacts:

Nick Rust / Lev Janashvilli

212-477-8439 / 212-227-7098

nrust@igbir.com / ljanashvili@igbir.com

Peregrine (PPHM) Completes Treatment of Last Patient in Phase II Cotara(R) Brain Cancer Trial

TUSTIN, CA — (Marketwire) — 12/20/10 — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the completion of enrollment in the company’s Phase II dose confirmation trial of Cotara® in patients with recurrent glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara is a targeted monoclonal antibody linked to a radioisotope that is administered as a single dose directly into the tumor, irradiating the tumor from the inside out, with minimal exposure to healthy tissue.

Interim median overall survival for patients treated with Cotara has ranged from 38 to 41 weeks, with 86 weeks from 14 patients at a single medical center. Expected survival is only approximately 24 weeks for recurrent GBM patients. Cotara has been granted orphan drug status and fast track designation for the treatment of GBM and anaplastic astrocytoma by the U.S. Food and Drug Administration.

“As currently approved therapies have failed to improve overall survival for recurrent GBM patients, the interim overall survival reported to date from our Cotara trials has been quite remarkable and we are eager to advance our treatment into a registrational trial,” said Joseph S. Shan, vice president of clinical and regulatory affairs at Peregrine. “We expect top-line data to be available by mid-year 2011 and plan to meet with the FDA to define the optimal registration pathway for Cotara.”

About Cotara
Cotara is an investigational targeted monoclonal antibody linked to a radioisotope that is administered as a single dose directly into the tumor, irradiating the tumor from the inside out, with minimal exposure to healthy tissue. Peregrine’s Phase II open-label trial was designed to enroll 40 GBM patients at first relapse at multiple sites in the U.S. and India. The primary endpoint is safety and tolerability of the maximum tolerated dose, a single 25-hour interstitial infusion of 2.5 mCi/cc of Cotara. Secondary endpoints include overall survival, progression free survival, and proportion of patients alive at six months after treatments.

About Brain Cancer
According to the American Cancer Society, in 2010 there will be an estimated 22,000 malignant tumors diagnosed and approximately 13,000 deaths attributed to brain or spinal cord cancer in the United States. The most common type of brain cancer is glioblastoma multiforme (GBM), which accounts for 60% of all malignant brain cancers. An aggressive form of cancer, GBM is the deadliest form of brain cancer, with a five-year survival rate of only 3%. Currently approved therapies include Temodar® (temozolomide) and Avastin® (bevacizumab), both of which have modest effect on patient survival.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals’ intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results from this trial will not be consistent with results experienced in earlier clinical trials and preclinical studies, the risk that results may not support registration filings with the U.S. Food and Drug Administration, and the risk that Peregrine may not have or raise adequate financial resources to complete the planned clinical programs. Factors that could cause actual results to differ materially or otherwise adversely impact the company’s ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2010 and the quarterly report on Form 10-Q for the quarter ended October 31, 2010. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Peregrine Contact:
Amy Figueroa
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com

Arena Pharmaceuticals (ARNA) Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension

SAN DIEGO, Dec. 10, 2010 /PRNewswire-FirstCall/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH.

“An orally bioavailable prostacyclin receptor agonist could improve the standard of care for patients with PAH, a life-threatening disorder,” said William R. Shanahan, M.D., Arena’s Senior Vice President and Chief Medical Officer. “APD811 is a non-prostanoid compound; in preclinical studies, the oral uptake, half life and efficacy characteristics suggest that it could offer improved administration over current prostacyclin receptor therapies.”

This randomized, double-blind and placebo-controlled Phase 1 trial is planned to enroll up to 72 healthy adult volunteers and will evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD811.

“While our primary focus is on achieving FDA approval of lorcaserin for weight management, we see value in advancing our promising earlier-stage compounds that may also address underserved medical needs,” said Jack Lief, Arena’s President and Chief Executive Officer. “With a measured investment, we aim to establish a favorable pharmacokinetic and preliminary safety profile for APD811 in this trial.”

About Pulmonary Arterial Hypertension (PAH)

PAH is a progressive, life-threatening disorder characterized by increased pressure in the arteries that carry blood from the heart to the lungs. The increased pressure puts a strain on the heart, which can lead to limited physical activity and a reduced life expectancy. Over time, the heart muscle weakens and can no longer pump blood efficiently. If PAH is not treated, the heart will eventually fail. Data from the National Institutes of Health Registry indicate that without treatment, patients in the United States with PAH have a median survival time of approximately three years from diagnosis.

About APD811

APD811, a potent and selective agonist (or activator) of the prostacyclin receptor, is Arena’s internally discovered drug candidate for the treatment of PAH. Prostacyclin receptor agonists, through regulation of vascular smooth muscle tone, improve mortality and exercise tolerance in PAH patients and are among the treatments administered as standard of care for advanced PAH. Currently available prostacyclin receptor agonists belong to the prostanoid class of molecules and these products need to be administered frequently or continuously through intravenous, subcutaneous or inhaled routes. Arena believes that APD811, as a non-prostanoid prostacyclin agonist, has the potential to improve the standard of care for PAH by providing an oral form of administration with clinical benefits similar to currently available prostacyclin receptor agonists.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena’s most advanced drug candidate, lorcaserin, is intended for weight management. Arena’s wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States following FDA approval of the New Drug Application for lorcaserin.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, safety, efficacy, tolerability, and mechanism of action of APD811; the potential of APD811 and orally bioavailable prostacyclin receptor agonists in general, including with regard to improving treatment; the protocol, design, scope, enrollment, potential results and other aspects of the Phase 1 clinical trial for APD811; Arena’s earlier-stage compounds and related value and potential; Arena’s focus on the approval of lorcaserin; the potential therapeutic indication and use, FDA approval and commercialization of lorcaserin; the Eisai collaboration and potential activities thereunder; and Arena’s aim, focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: there was a small safety margin from the no observed adverse effect level to significant adverse events in preclinical studies of APD811, and APD811 could have an unacceptable safety and efficacy profile in humans; the risk that regulatory authorities may not find data and other information related to Arena’s clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena’s response to the complete response letter for the lorcaserin NDA may not be submitted in a timely manner or the information provided in such response may not satisfy the FDA; the FDA may request additional information prior to approval of the lorcaserin NDA; unexpected new data; risks related to commercializing new products; Arena’s ability to obtain and defend its patents; the timing, success and cost of Arena’s research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena’s ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena’s forward-looking statements are disclosed in Arena’s filings with the Securities and Exchange Commission. These forward-looking statements represent Arena’s judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Icagen (ICGN) and Pfizer Initiate Phase I Trial in Nav1.7 Program

RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2010 (GLOBE NEWSWIRE) — Icagen, Inc. (Nasdaq:ICGN) today provided an update on its sodium channel program for pain and related disorders, which is being conducted in collaboration with Pfizer. As previously reported, the companies recently selected a candidate compound to advance into further clinical studies. Dosing of this candidate compound has now been initiated in a Phase I study in healthy volunteers.

The safety, tolerability, pharmacokinetics and optimal formulation of the candidate compound will be assessed during a placebo controlled dose escalation in two cohorts of healthy volunteers; exploratory pharmacodynamic end points will be investigated in a third cohort of healthy volunteers.

P. Kay Wagoner, CEO of Icagen, stated, “We are delighted that, in collaboration with Pfizer, we have now initiated Phase I clinical studies of our potent and subtype-selective Nav1.7 compound. This marks another important milestone in our development of subtype-selective sodium channel blockers, which we believe represent a promising approach for the treatment of pain and related disorders.”

Pfizer will continue to fund all aspects of the collaboration, including all clinical studies and the continuing research and preclinical development efforts at Icagen on collaboration sodium channel targets. Pfizer has exclusive worldwide rights to commercialize products that result from the collaboration. Icagen is eligible to receive milestones and tiered royalties based upon product sales for each product under the collaboration.

About Icagen

Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. The Company has a clinical stage program in epilepsy and pain. To learn more about Icagen, please visit our website at www.icagen.com.

The Icagen, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5735

Forward-Looking Statements

This press release may contain forward-looking statements that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” and similar expressions are intended to identify forward-looking statements. Important factors that could cause actual results to differ materially from the expectations described in these forward-looking statements are set forth under the caption “Risk Factors” in Icagen’s most recent Quarterly Report on Form 10-Q, filed with the SEC on November 10, 2010. These risk factors include risks as to Icagen’s lack of liquidity and substantial doubt about Icagen’s ability to continue as a “going concern”; Icagen’s ability to raise additional funding; Icagen’s history of net losses and how long Icagen will be able to operate on its existing capital resources; general economic and financial market conditions; Icagen’s ability to maintain compliance with Nasdaq’s continued listing requirements; whether Icagen’s product candidates will advance in the clinical trials process; the timing of such clinical trials; whether the results obtained in preliminary studies will be indicative of results obtained in clinical trials; whether the clinical trial results will warrant continued product development; whether and when, if at all, Icagen’s product candidates, including ICA-105665 and Icagen’s other lead compounds for epilepsy and pain, will receive approval from the U.S. Food and Drug Administration or equivalent regulatory agencies, and for which indications, and if such product candidates receive approval, whether such products will be successfully marketed; and Icagen’s dependence on third parties, including manufacturers, suppliers and collaborators. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

CONTACT:  Icagen, Inc.
          Richard D. Katz, M.D., EVP, Finance and
           Corporate Development; Chief Financial Officer
          (919) 941-5206
          rkatz@icagen.com

Fronteer Gold (FRG) Enters Into Agreement to Sell Its Uranium Assets to Paladin Energy

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 12/17/10 — Fronteer Gold Inc. (TSX: FRG)(NYSE Amex: FRG) announces today it has entered into an Asset Sale Agreement under which Paladin Energy Ltd. (ASX: PDN)(TSX: PDN) will acquire 100% of the uranium assets of Aurora Energy Resources Inc., a wholly owned subsidiary of Fronteer Gold.

Under the terms of the Agreement, Fronteer Gold will receive 52.1 million common shares of Paladin valued at C$260.87 million, calculated using the recent five-day volume weighted average price of Paladin common shares on the TSX. Upon closing, Fronteer Gold will be the largest Paladin shareholder at approximately 6.7%. Closing of the transaction is expected in the first quarter 2011 and remains subject to applicable regulatory approvals, including approval of the TSX.

This transaction is consistent with Fronteer Gold’s stated goal of becoming a significant gold producer in Nevada, and allows management to focus time and resources on advancing the company’s recently consolidated flagship Long Canyon project and wholly owned Northumberland project.

“This transaction crystallizes significant value for Fronteer Gold’s uranium assets,” says Mark O’Dea, President and CEO of Fronteer Gold. “Paladin is uniquely positioned to advance Aurora’s Michelin Project by virtue of their demonstrated development skills, excellent financial strength and strong track record of social and environmental stewardship in communities in which they operate. With this world-class project added to their development pipeline, we believe Paladin will have one of the most exciting production growth profiles in the uranium industry. This transaction gives us the option of maintaining exposure to the uranium price through a meaningful shareholding in a high-quality, diversified uranium producer. Ultimately, this capital will be deployed to build out our Nevada gold projects, leaving our company in an exceptionally strong strategic and financial position.”

John Borshoff, Managing Director and CEO of Paladin comments: “We welcome Fronteer Gold as our largest shareholder and acknowledge the quality of work completed moving Aurora’s uranium assets forward. Paladin remains one of the few independent global uranium producers and this acquisition provides geographic diversification and a world-class asset located in Canada, a leader in global uranium production. Paladin plans to advance these assets in accordance with our communicated growth strategies, thus benefiting all shareholders, customers and the stakeholders of Nunatsiavut, Newfoundland and Labrador.”

ABOUT FRONTEER GOLD

We intend to become a significant gold producer. Our future potential production platform includes our Long Canyon, Sandman and Northumberland projects – all located in Nevada. We also have a 40% interest in Halilaga, an emerging copper-gold porphyry deposit in northwestern Turkey. For further information on Fronteer Gold, visit www.fronteergold.com.

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including but not limited to, those with respect to potential expansion of mineralization, potential size of mineralized zone, potential type of mining operation and timing and size of exploration and development programs involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement of Fronteer Gold to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks related to the actual results of current exploration activities, conclusions of economic evaluations, uncertainty in the estimation of ore reserves and mineral resources, changes in project parameters as plans continue to be refined, future prices of gold and silver, environmental risks and hazards, increased infrastructure and/or operating costs, labor and employment matters, and government regulation and permitting requirements as well as those factors discussed in the section entitled “Risk Factors” in Fronteer Gold’s Annual Information form and Fronteer Gold’s latest Form 40-F on file with the United States Securities and Exchange Commission in Washington, D.C. Although Fronteer Gold has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Fronteer Gold disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Accordingly, readers should not place undue reliance on forward-looking statements.

NEWS RELEASE 10-44

Contacts:
Fronteer Gold
Mark O’Dea
President & CEO
604-632-4677 or Toll Free 1-877-632-4677

Fronteer Gold
John Dorward
VP, Business Development
604-632-4677 or Toll Free 1-877-632-4677

Fronteer Gold
Patrick Reid
Senior Director, Institutional Marketing
604-632-4677 or Toll Free 1-877-632-4677
info@fronteergold.com
www.fronteergold.com

Chairman of Kandi Technologies (KNDI) Reiterates Growth Plans at 2010 Annual Meeting of Shareholders

JINHUA, CHINA — (Marketwire) — 12/17/10 — Kandi Technolgies, Corp. (NASDAQ: KNDI) (“Kandi” or the “Company”), a leading Chinese exporter of all terrain recreational vehicles, developer of the “CoCo” all electric LSV, and a leader in Electric Vehicle (EV) development in China, held its 2010 Annual Meeting in Hong Kong on December 17. Shareholders elected seven directors, including two new independent directors and ratified the appointment of Albert Wong & Co. as corporate auditor for fiscal year 2010.

The three re-elected directors who also serve as corporate officers are Mr. Hu Xiaoming, Chairman of the Board, CEO and President, Mr. Hu Wangyuan, Vice President and Director, and Ms. Zhu Xiaoying, Chief Financial Officer and Director.

Two independent directors, Mr. Zheng Mingyang and Mr. Yao Zhengming, were re-elected. In the addition, the new independent Board members replacing two retiring directors are:

Mr. Jerry Lewin, Senior Vice President of Field Operations for Hyatt Hotels Corporation, who is responsible for 35 hotels throughout North America. He has been with Hyatt since 1987. In his day-to-day operations, Mr. Lewin oversees finance, sales and marketing, public relations, customer service, engineering and human resources. He also serves as a member of Hyatt’s Managing Committee. He is a director of the New York City Hotel Association, President of The New York Law Enforcement Association, President of the NYS Troopers PBA Signal 30 Fund and a former Trustee of Metropolitan College. Mr. Lewin received his Bachelor of Science degree from Cornell University and completed the Executive Development Program at J.L. Kellogg Graduate School of Management at Northwestern University.

Prominent EV expert, Professor Ni Guangzheng, who is a Deputy Director of the Technical Committee and Director of the EV Research Institute of the National ERC of Power Electronic Technology since 1998. Previously, Professor Ni was head of the Department of Electrical Engineering at Zhejiang University from 1994-1998 and has held numerous other high level academic and scientific positions. Additionally, he has published ten textbooks, more than 160 journal and conference papers and holds one patent. He also has received numerous awards and prizes for his research in electromagnetics and electrical engineering including two first class prizes in 1996 and 2007 awarded by the Ministry of Education.

Mr. Hu welcomed the new independent directors and stated, “Our four independent directors will provide investor perspective to the Board and reflect our interest in maintaining and improving Kandi’s corporate governance practices and transparency to best serve the interest of all shareholders.”

Growth Plans Reiterated

In his address to shareholders at the meeting, Mr. Hu reiterated the Company’s previously announced growth forecast of “revenues reaching or exceeding $40 million,” for 2010, which he noted would be close to a record for the Company.

Mr. Hu also commented on the “tremendous demands” for clean energy and energy saving products in China such as Kandi’s battery powered vehicle, the KD5010 and other models the Company may develop. He stated, “We anticipate growing interest in our EV from various local municipal services such as the Postal Service. At the same time, we will look to expand our Chinese consumer base, and to derive revenues from auto sales as well as from servicing the cars working with our joint venture partners.”

Mr. Hu concluded, “Longer term, the outlook for Kandi is very bright. Around the world there is growing interest in electric vehicles and our ‘Express Change’ business model. We strive to be a leading market player in this space, not only with the introduction of KD 5010EVs for Chinese consumers and the CoCo for the U.S. and other countries, but also with continuing innovations throughout the year. Great design and innovation always have been hallmarks of our Company — and this will continue to be the case in the future.”

The full text of Mr. Hu’s comments is available in an 8-K being filed today with the U.S. Securities and Exchange Commission and may be viewed at www.sec.gov.

About Kandi Technologies, Corp.

Kandi Technologies, Corp. (NASDAQ: KNDI) ranks as one of the largest manufacturers and exporters of go-karts in China, making it a world leader in the production of this popular recreational vehicle. It also ranks among the leading manufacturers in China of all terrain vehicles (ATVs), and specialized utility vehicles (UTVs), especially for agricultural purposes. Recently, it introduced a second generation high mileage, two seater three-wheeled motorcycle. A major company focus also has been on the manufacture and sales of highly economical, beautifully designed, all electric super mini cars for neighborhood driving and commuting. Available in the U.S., convertible and hardtop models of the CoCo travel up to 60 miles at speeds reaching 25mph on a six hour charge. In China, the government recently approved the sale there of Kandi EVs, including the larger, more powerful KD5010, now being sold in Jinhua City, where the city’s first “Battery Charging Farm” and “Express Change” battery station has opened. This and planned additional “Express Change” battery stations are operated by a pioneering three partner joint venture in which Kandi holds a 30% interest with China’s leading battery maker, Tianneng Power International, Ltd., and Jinhua Bada Group, a subsidiary of State Grid Power Corporation, China’s largest power company. Participation in China’s first Electric Vehicle (EV) battery replacement services company will mean the development of two revenue streams for Kandi — one from the sale of its battery-powered vehicles and the other from a share of the battery rental, replacement, charging and recycling fees generated by the new joint venture. Kandi believes that battery powered, electric super minis and related services will become the Company’s largest revenue and profit generator. The Company’s products can be viewed at http://www.kandivehicle.com. Its corporate/ir website is http://www.chinakandi.com.

Information Regarding Forward-Looking Statements

Except for historical information contained herein, the statements in this Press Release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the Securities and Exchange Commission.

Contacts:

Kandi Technologies, Corp.
Xiaoming Hu
Chairman and CEO
86-579-82239856

Cathy Cao
Executive Vice President of Finance
Cathy_kndi@yahoo.com
Tel: 212-551-3610

IR Firm:

Ken Donenfeld
donfgroup@gmail.com
kdonenfeld@dgiir.com
Tel: 212-425-5700
Fax- 646-381-9727

InterMune (ITMN) Announces Senior Leadership Appointments to Prepare for Launch of Esbriet(TM) (Pirfenidone) in Europe

InterMune, Inc. today announced additions to its senior leadership team to prepare for the commercialization of Esbriet(TM) (pirfenidone) in Europe. InterMune’s Marketing Authorization Application (MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, “We are very pleased by the high quality of candidates who are interested in joining our European organization which will be headquartered in Basel, Switzerland. The individuals announced today are very accomplished and seasoned pharmaceutical executives who will be the part of our team that will prepare our organization to successfully launch Esbriet in Europe. We will continue to move quickly to prepare to launch the first approved therapy in Europe in adults for the treatment of mild to moderate Idiopathic Pulmonary Fibrosis (IPF).”

EU Leadership Appointments

InterMune announced the following additions to its leadership team: – Senior Vice President and Managing Director, Europe – Giacomo Di Nepi. Mr. Di Nepi joined InterMune in this role in November of 2009. Before Joining InterMune he was Chief Executive Officer of Takeda Pharmaceuticals Europe, where he drove the EU operations and geographic expansion. Prior to that, Mr. Di Nepi was a member of the Executive Committee of Novartis Pharma AG as Global Head for the Transplantation and Infectious Disease business unit. He previously served as Chief Executive Officer of Novartis Italy. Before entering the pharmaceutical industry, he was a partner in the healthcare practice of McKinsey & Co. Mr. Di Nepi will be based in the European headquarters in Basel, Switzerland and has worked in Switzerland, the UK, the US and Italy. The following executives will report to Mr. Di Nepi. – Senior Vice President, EU Medical and Global Medical Advisor – Frank T. Weber, M.D. Dr. Weber has 20 years of industry experience, having served most recently as Chief Medical Officer at Merck Serono where he played a key role in the registration and reimbursement processes in Europe for Erbitux(R) (cetuximab). Dr. Weber previously served in various medical affairs positions at American Cyanamid/Lederle, Sythelabo and Merck KGaA. He also worked on the national reimbursement side as Medical Director with MedNet, a Munich Re/United Health Care joint venture. Dr. Weber began his career in healthcare as a surgeon and immunologist. Dr. Weber has worked in Germany, Switzerland, France, the UK and the United States. He will be based in the European headquarters in Basel, Switzerland. – Senior Vice President and General Manager, Germany – Markus Leyck Dieken, M.D. Dr. Dieken joins InterMune from Novartis, where he was Head of the European Region for the vaccines business and Managing Director of Novartis-Behring’s German operations. Prior to Novartis, he served for 10 years with Novo Nordisk Germany in various roles in Medical Affairs, Marketing and Sales, and then as General Manager of the German subsidiary and Vice President, Central Europe. He has worked in Germany and Switzerland. Dr. Leyck Dieken will be based in Berlin, Germany. – Vice President, Sales and Marketing, Europe – Ms. Manuela Maronati. Ms. Maronati brings 15 years of sales and marketing experience, including the past seven years with Amgen where she served as an International Senior Marketing Manager on the Neupogen(R) (filgrastim) franchise, and where she previously launched a new medical device for use across several Amgen products. She has worked in Switzerland, the UK and Italy. Ms. Maronati will be based in the European headquarters in Basel, Switzerland.

InterMune also announced that the headquarters of its European operations will be Basel, Switzerland and that the company has now established subsidiaries in Germany, Italy and the United Kingdom that are licensed to conduct business and is in the process of finalizing the establishment of subsidiaries in France and Spain. InterMune plans to have a focused organization in Europe of approximately 125 full-time personnel by the end of 2012, supported by expert consultants and third-party service providers. Active recruitment is now underway for the countries that will first launch Esbriet, Germany and France, and InterMune expects to begin to recruit additional personnel starting in January 2011 for the Top 10 EU countries. Additional hiring will continue in a rolling fashion based on the timing of reimbursement and pricing reviews in those countries.

Conference Call and Webcast Details

InterMune will host a conference call today at 8:30 a.m. EST to discuss Esbriet (pirfenidone) and the related Marketing Authorization Application. Interested investors and others may participate in the conference call by dialing 888-567-5125 (U.S.) or +1-706-643-9223 (international), conference ID# 33188579. A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company’s website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or +1-706-645-9291 (international), and entering the conference ID# 33188579. The webcast will remain available on the company’s website until the next earnings call.

About Esbriet (pirfenidone)

Preclinical and in-vitro evidence has shown that Esbriet has both anti-fibrotic and anti-inflammatory effects. In February 2009, InterMune announced the results of the company’s two pivotal Phase 3 clinical trials evaluating Esbriet for the treatment of IPF, known as the CAPACITY trials. In clinical studies, Esbriet was safe and generally well-tolerated, with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms. Since 2008, pirfenidone has been marketed in Japan as Pirespa(R) by Shionogi & Co. Ltd.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes Esbriet(TM) (pirfenidone) for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY). The Marketing Authorization Application (MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission. The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune’s judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to the anticipated receipt of marketing authorization approval from the European Commission for the use of pirfenidone for the treatment of IPF and the expected timing thereof, statements regarding commercial launch preparations and statements regarding the various anticipated durations of patent protection and marketing exclusivity. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune’s actual results could differ materially from those described in InterMune’s forward-looking statements.

Other factors that could cause or contribute to such differences include, but are not limited to, (i) whether the European Commission approves the marketing authorization for pirfenidone for the treatment of IPF and the actual timing of the decision; (ii) risks related to unexpected regulatory actions or delays or government regulation generally; (iii) risks related to the clinical and regulatory process for pirfenidone, including having no unexpected safety, toxicology, clinical or other issues; (iv) unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; (v) government, industry and general public pricing pressures; (vi) InterMune’s ability to obtain or maintain patent or other proprietary intellectual property protections; (vii) risks related to building the infrastructure required for commercial launch in various countries in the European Union, and (viii) those other factors discussed in detail under the heading “Risk Factors” in InterMune’s most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 15, 2010 (the “Form 10-K”), and other periodic reports filed with the SEC. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune’s other periodic reports filed with the SEC, all of which are available via InterMune’s web site at http://www.intermune.com.

Esbriet is registered trademark of InterMune, Inc.

Neuralstem (CUR) Receives FDA Approval to Commence Drug Trial for Major Depression

Claude Resources (CGR) Continues to Expand THE AMISK GOLD Deposit, Saskatchewan

SASKATOON, Dec. 16 /CNW/ – Claude Resources Inc. (TSX-CRJ; NYSE Amex-CGR) (“Claude” or the “Company”) is pleased to announce results from sampling in excess of 22,000 metres of drill core from a total of 278 historic drill holes on the 13,900 hectare Amisk Gold Property.

The Amisk Gold Project is located 20 kilometres southwest of Flin Flon, Manitoba and is a 65:35 Joint Venture between Claude and St. Eugene Mining Corporation; Claude is the operator of the Joint Venture. The 2010 exploration program was focused on the Amisk Gold Deposit, specifically evaluating the bulk mining potential of the system and expanding the deposit.

Initial evaluation and compilation of historic assays in early 2010 revealed 148 composite intervals greater than a 20 gram metre product* (See Claude News Release dated May 12^th, 2010). Geological modeling and analysis of the drill data indicated that historic sampling focused on high grade vein systems leaving a broad envelope of mineralization largely unsampled.  Subsequent sampling of this drill core during 2010 confirmed grade continuity, expanded the mineralized system and yielded 244 composite intervals greater than a 20 gram metre product from the 278 historic drill holes.  Highlights of up to 241 metres at 2.16 g/t gold and 18.9 g/t silver are presented below in Table 1 with a complete composite list available on the Company’s website (www.clauderesources.com).

“These impressive results in conjunction with geological compilation and modeling outline an extensive, bulk-mineable gold system.  The system remains open along strike to the northeast, southwest, southeast and down-dip,” stated Brian Skanderbeg, Vice President Exploration.  “Based on continuing positive results, the Joint Venture has elected to pursue an initial 43-101 resource. This will be the first step in demonstrating the scope of the Amisk Gold Deposit.”

This sampling and verification process will allow the Company to utilize the historic drill data as well as 21 drill holes completed during 2010 to generate a National Instrument 43-101 compliant Resource and Technical Report. SRK Consulting of Toronto has been engaged to complete the Resource Study and Technical Report. Completion of the resource study is anticipated late in the first quarter of 2011.

Table 1: Highlights of historic drill results from the Amisk Gold deposit.

Note: Intervals noted are intercepted width not true width, have been calculated using a 0.3 g/tonne cut-off and are uncut. Subintervals are presented if greater than 10 gram-metre product with variable cut-offs. True width is variable between 50 and 100 percent of drilled width.  They may include internal dilution and/or unsampled intervals.  Unsampled intervals have been treated at zero grade for the purpose of composite calculation. Total width of unsampled intervals are noted. Historic assay results have been verified to the original assay certificate where possible. Quality Assurance and Quality Control procedures, inclusive of twin holes, quartered core sampling as well as insertion of blanks, standards and duplicates has been completed.

The Amisk Gold Deposit is hosted within a rhyolite flow-dome complex and overlying pyroclastic tuffs of the Amisk Volcanic Assemblage, Flin Flon Greenstone Belt. High grade gold and silver mineralization is hosted within a series of moderately to shallowly-dipping, pyrite +/- chalcopyrite-sphalerite-tetrahedrite-galena-bearing sulphide vein systems. High grade vein systems are typically flanked by wide intervals of low grade disseminated and stringer mineralization within a broad sericite alteration envelope. A detailed plan map and cross section of the Amisk Gold Deposit are presented on the Company’s website (www.clauderesources.com).

In addition to the winter 2010 drill program and the summer historic core sampling, a 10 hole, 3,300 metre fall exploration program was completed in early November. Assay results are currently pending. The program was designed to evaluate the northeastern, southwestern and southeastern strike extensions as well as complete several infill holes within the western portion of the deposit.

In addition to advancing the Amisk Gold Project, Claude continues to focus on expanding the production profile and resource base at the Seabee Operation and plans to initiate Phase II underground drilling at the Madsen Property in Red Lake during the first quarter 2011.  The program is designed to test depth and strike extensions to high grade mineralization within the 8 Zone Trend.

Claude Resources holds approximately 12 percent interest in St. Eugene’s issued and outstanding common shares as of December 14, 2010.

* Note that gram-metre product reflects the multiple of intercepted gold grade and core length. It is a measure of contained gold within a given interval. A 20 gram-metre product has been used as a cut-off.

Brian Skanderbeg, P.Geo. and M.Sc., Claude’s Vice-President Exploration, is the Qualified Person who has reviewed and approved the contents of this news release. Drill core was halved and/or quartered with samples averaging 2.0 metres submitted to ALS Chemex in Vancouver and/or TSL Laboratories in Saskatoon, Saskatchewan, both ISO approved facilities. Rigorous quality assurance and quality control procedures have been implemented including the use of blanks, standards and duplicates. Core samples were analyzed by a 30 gram gold fire assay with an atomic absorption, conventional gravimetric and/or screen fire techniques.

Claude Resources Inc. is a public company based in Saskatoon, Saskatchewan, whose shares trade on the Toronto Stock Exchange (TSX-CRJ) and the NYSE Amex (NYSE Amex-CGR). Claude is a gold exploration and mining company with an asset base located entirely in Canada. Since 1991, Claude has produced approximately 915,000 ounces of gold from its Seabee mining operation in northeastern Saskatchewan. The Company also owns 100 percent of the 10,000 acre Madsen property in the prolific Red Lake gold camp of northwestern Ontario and has a 65 percent working interest in the Amisk Gold Project in northeastern Saskatchewan.

CAUTION REGARDING FORWARD-LOOKING INFORMATION

This Press Release may contain ‘forward-looking’ statements regarding the plans, intentions, beliefs and current expectations of the Company, its directors, or its officers with respect to the future business activities and operating performance of the Company.  The words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions, as they relate to the Company, or its management, are intended to identify such forward-looking statements.  Investors are cautioned that any such forward-looking statements are not guarantees of future business activities or performance and involve risks and uncertainties, and that the Company’s future business activities may differ materially from those in the forward-looking statements as a result of various factors.  Such risks, uncertainties and factors are described in the periodic filings with the Canadian securities regulatory authorities, including the Company’s Annual Information Form and quarterly and annual Management’s Discussion & Analysis, which may be viewed on SEDAR at www.sedar.com.  Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.  Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not anticipated, estimated or intended.  The Company does not intend, and does not assume any obligation, to update these forward-looking statements.

CAUTIONARY NOTE TO US INVESTORS CONCERNING RESOURCES ESTIMATES

The resource estimates in this document were prepared in accordance with National Instrument 43-101, adopted by the Canadian Securities Administrators. The requirements of National Instrument 43-101 differ significantly from the requirements of the United States Securities and Exchange Commission (the “SEC”). In this document, we use the terms “measured,” “indicated” and “inferred” resources. Although these terms are recognized and required in Canada, the SEC does not recognize them. The SEC permits US mining companies, in their filings with the SEC, to disclose only those mineral deposits that constitute “reserves”. Under United States standards, mineralization may not be classified as a reserve unless the determination has been made that the mineralization could be economically and legally extracted at the time the determination is made. United States investors should not assume that all or any portion of a measured or indicated resource will ever be converted into “reserves.” Further, “inferred resources” have a great amount of uncertainty as to their existence and whether they can be mined economically or legally, and United States investors should not assume that “inferred resources”.

Neil McMillan, President & CEO
Phone: (306) 668-7505
or
Brian N. Skanderbeg, P.Geo, Vice President Exploration
Phone: (306) 668-7505

Email: ir@clauderesources.com
Website: www.clauderesources.com

Stewardship Financial Corporation (SSFN) Declares Cash Dividend

MIDLAND PARK, NJ — (Marketwire) — 12/16/10 — The Board of Directors of Stewardship Financial Corporation (NASDAQ: SSFN), parent company of Atlantic Stewardship Bank, has declared a $0.05 per share cash dividend. Common stockholders of record as of January 14, 2011 will be paid the dividend on February 1, 2011.

In announcing the dividend, Chairman William C. Hanse stated, “We are pleased to continue to recognize our shareholders with this dividend. The board remains diligent in monitoring the Corporation’s dividends during these uncertain economic times.”

Paul Van Ostenbridge, President and Chief Executive Officer, continued, “Management is constantly monitoring all challenges to mitigate potential problems in the future. The Board of Directors remains committed to providing value to our shareholders as well as giving back to the community through the bank’s unique tithing mission.”

Stewardship Financial Corporation’s subsidiary, Atlantic Stewardship Bank is celebrating its twenty-fifth year of service and has 13 banking offices in Midland Park, Hawthorne (2 offices), Montville, North Haledon, Ridgewood, Pequannock, Waldwick, Wayne (3 offices), Westwood and Wyckoff, New Jersey. Please visit our website at www.asbnow.com or call 201-444-7100 for information regarding our products and services.

Contact:
Mary Beth Steiginga
630 Godwin Avenue
Midland Park, NJ 07432
201-444-7100

OCZ (OCZ) Announces Certain Shareholders Execute Agreements for Private Sale of OCZ Common Stock

SAN JOSE, Calif., Dec. 16, 2010 (GLOBE NEWSWIRE) — OCZ Technology Group, Inc. (Nasdaq:OCZ), a leading provider of high-performance solid-state drives (SSDs) and memory modules for computing devices and systems, today announced that certain shareholders of OCZ Technology Group, Inc. have signed definitive agreements with various institutional and accredited investors for the sale of OCZ common stock. OCZ will not receive any of the proceeds of such sale.

OCZ agreed to file a registration statement with the Securities and Exchange Commission, registering the resale of these shares following the close of the transaction.

About OCZ Technology Group, Inc.

Founded in 2002, San Jose, CA-based OCZ Technology Group, Inc. (“OCZ”), is a leader in the design, manufacturing, and distribution of high performance and reliable Solid-State Drives (SSDs) and premium computer components. OCZ has built on its expertise in high-speed memory to become a leader in the SSD market, a technology that competes with traditional rotating magnetic hard disk drives (HDDs). SSDs are faster, more reliable, generate less heat and use significantly less power than the HDDs used in the majority of computers today. In addition to SSD technology, OCZ also offers high performance components for computing devices and systems, including enterprise-class power management products as well as leading-edge computer gaming solutions. For more information, please visit: www.ocztechnology.com.

The OCZ Technology Group, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7439

Forward-Looking Statements Certain statements in this release relate to future events and expectations and as such constitute forward-looking statements involving known and unknown factors that may cause actual results of OCZ Technology Group, Inc. to be different from those expressed or implied in the forward-looking statements. In this context, words such as “will,” “would,” “expect,” “anticipate,” “should” or other similar words and phrases often identify forward-looking statements made on behalf of OCZ. It is important to note that actual results of OCZ may differ materially from those described or implied in such forward-looking statements based on a number of factors and uncertainties, including, but not limited to, market acceptance of OCZ’s products and OCZ’s ability to continually develop enhanced products; adverse changes both in the general macro-economic environment as well as in the industries OCZ serves, including computer manufacturing, traditional and online retailers, information storage, internet search and content providers and computer system integrators; OCZ’s ability to efficiently manage material and inventory, including integrated circuit chip costs and freight costs; and OCZ’s ability to generate cash from operations, secure external funding for its operations and manage its liquidity needs. Other general economic, business and financing conditions and factors are described in more detail in “Item 1A — Risk Factors” in Part II in OCZ’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2010. The filing is available both at www.sec.gov as well as via OCZ’s website at www.ocztechnology.com. OCZ does not undertake to update its forward-looking statements.

CONTACT:  OCZ Technology Group, Inc.
          Bonnie Mott, Investor Relations Manager
          408-733-8400

          The Investor Relations Group
          Investor Relations:
          Adam Holdsworth
          Public Relations:
          Mike Graff
          212-825-3210

Axcelis Integra(TM) (ACLS) ES Plasma Dry Strip System Selected as Process Tool of Record

BEVERLY, Mass., Dec. 16, 2010 (GLOBE NEWSWIRE) — Axcelis Technologies, Inc. (Nasdaq:ACLS) today announced that its Integra^TM ES plasma dry strip system has been selected as the process tool of record by one of the world’s largest semiconductor manufacturers.  The company has received the first in a series of orders for the system to support the customer’s 32nm and 28nm technology manufacturing capacity expansion. The orders will begin shipping in December 2010.

“The Integra ES was selected to perform photoresist strip levels over sensitive high-K and metal gate materials, after an extensive evaluation and process development program. Our customer was attracted to the device performance benefits achieved when running the resist strip processes over sensitive gate stack materials with non-oxidizing chemistries,” said Bill Bintz, senior vice president of marketing for Axcelis Technologies.  “Combined with the Integra ES’ unique ability to execute these advanced processes in a repeatable, reliable manner, the product is ideally suited for high volume manufacturing for the most advanced IC devices.”

Axcelis’ dry strip cleaning product portfolio includes the Integra RS and ES systems as well as the Rapidstrip^TM 320 and 210 systems.   Together, these products deliver highly differentiated plasma cleaning technology to meet the full range of customer needs, from the highest productivity, non-oxidizing solutions for 32nm and below chip makers, to single chamber, small substrate size applications in the MEMS, LED, and packaging markets.

Axcelis Technologies, Inc. (Nasdaq:ACLS) headquartered in Beverly, Massachusetts, provides innovative, high-productivity solutions for the semiconductor industry. Axcelis is dedicated to developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation and cleaning systems. The company’s Internet address is: www.axcelis.com.

CONTACT:  Axcelis Technologies, Inc.
          Editorial/Media
          Maureen Hart
            978.787.4266
          Financial Community
          Stephen Bassett
            978.787.4000

Metalline (MMG) Reports on Eastern Extension of Area A Silver (+Zinc+Lead) Resource Area

GREENWOOD VILLAGE, Colo., Dec. 15, 2010 /PRNewswire-FirstCall/ — Metalline Mining Company (Amex: MMG; TSX: MMZ) is pleased to announce further results from the evaluation of earlier drilling programs at the shallow silver-zinc resource area (“Area A”) at the Sierra Mojada Project located in Coahuila, Mexico.  Results reported below are at a 30 gpt Ag or 1% Zn external cut-off.

Metalline reports a total of  340 drill holes, most of them short underground “long” holes drilled in 2006 from access within the Area A silver (+zinc+lead) resource, that average 13 meters thick above a 30 gpt Ag cut-off, averaging 110 gpt Ag, 1.18% Zn, and 0.44% Pb.  Most of these holes are only 2-22 meters long, and drill only a portion of the true thickness of the resource, which averages 25-30 meters thick in the area between sections 631700E and 632550E.  This portion of the resource may be potentially minable from either underground or by open pit.  If mineable by open pit the stripping to access this portion of the Area A silver(+zinc+lead) resource will expose the deeper and larger zinc oxide deposit and greatly reduce the stripping required to fully access the zinc oxide deposit.

Sections 631700E, through 632550E compliment assays sections that were reported earlier.  Metalline has now reported assays sections covering the area between sections 629600E and 632550E on the Area A silver(+zinc+lead) resource, a distance of three kilometers, with a few intervening sections remaining to be compiled.   The results from these remaining sections will be reported as compilation by section is completed.   The continuity and potential minability of the silver zone on these sections is demonstrated on the individual graphic sections and the composite panel section diagrams posted to the web site at http://www.metallinemining.com/s/DH_Sections.asp.

All of the sampling and sample preparation for assays reported herein have been done on site under supervision by Metalline personnel and all those samples were shipped directly to ALS-Chemex for further sample preparation and assaying with insertion of appropriate standards and blanks. A third party review of the Company’s QA/QC program vetted the Company’s sample preparation and sample handling protocols for the previous core drilling and channel sampling programs, but did not specifically address sampling from the 2006 long hole drilling program.  A surface core drilling program is planned for 2011 to test and confirm the geometry and grade of the resource area reported herein.

Greg Hahn, Interim President and CEO, a Certified Professional Geologist, is the Qualified Person responsible for reviewing and reporting the contents of this press release and assuring the results reported herein are in accordance with NI 43-101.

Detailed drill results by section are attached below: